PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes
Services Improve the Information Available to Oncologists and Pathologists in Determining Patient Risk Profiles and Treatment Diagnostic Industry Veteran Wayne Brinster Joins as CEO PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, …
Linus Biotechnology Inc. Receives FDA Breakthrough Device Designation for StrandDx™-ASD Exposome Sequencing Diagnostic
Linus Biotechnology Inc., a leader in precision exposome sequencing, today announced that the U.S. Food and Drug Administration Center for Devices and Radiological Health has granted the Company’s StrandDx™-ASD diagnostic aid the designation as a Breakthrough Device for Autism Spectrum Disorder (ASD). …
Mount Sinai Spin-Off Linus Biotechnology Inc. to Revolutionize Precision Medicine with Exposome Sequencing
Linus Biotechnology Inc. and Mount Sinai Innovation Partners (MSIP) today announced an exclusive worldwide license and collaboration agreement in progress with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai), the medical school of the Mount Sinai Health System (Mount …
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
Sema4, an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for postpartum hemorrhage (PPH). The studies, which will appear in a special “Informatics for Sex- and Gender-Related Health” …
BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancers
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia University and Mount Sinai (Icahn Mount Sinai) to translate cutting-edge research discoveries into potential therapies for patients with genetic diseases and genetically driven cancers. “Columbia …
New Partnership Agreement & Licensed Clinical Team Established with Three Senior Hires
Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, announces it has established a management services organization agreement with Connected Health Medicine PC (“Connected Health”), a state licensed Professional Corporation that will …
Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™ early-stage risk assessment testing and care management …
First Demonstration Contract with Mount Sinai Employee Health Plan for Resilience-Based Digital Chronic Condition Management
Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, is pleased to announce that it has signed an agreement to provide an Inflammatory Bowel Disease (“IBD”) demonstration programme for the Mount Sinai …
Mount Sinai Health System Launches Elementa Labs, A Virtual Incubator Program
Elementa Labs will connect health care startup companies with Mount Sinai’s vast network of research and clinical experts to advance groundbreaking health care innovations. Mount Sinai Innovation Partners (MSIP), the commercialization engine of the Mount Sinai Health System (Mount Sinai) in New …
Kantaro’s Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order
-COVID-SeroKlir detects both the presence and precise level of neutralizing IgG antibodies with 98.8% sensitivity and 99.6% specificity -Available immediately and can be used in Canadian laboratories without proprietary equipment Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health …